Chronic kidney disease and COVID-19 infection: A case–Control study

To organize efforts to manage the coronavirus disease 2019 (COVID‑19), it is necessary to understand which groups are at higher risk of infection. Kidney disease seems to be substantial in COVID‑19 patients, but there are limited data on COVID‑19 incidence and fatality among chronic kidney disease (CKD) patients. In this study, we intend to examine the association between CKD and susceptibility to COVID‑19 infection.

Participants were selected from those recruited in a population‑based cross‑sectional survey of CKD prevalence and associated risk factors in Iranian people 18 years and older. A three‑part questionnaire was used for COVID‑19 infection clinical symptoms and epidemiologic and hospitalization data.

A total of 962 individuals including 403 CKD patients and 559 healthy controls were recruited in this study. Healthy controls were suffering more from common cold signs, cough, fever, sore throat, headache, anosmia, dyspnea, and abdominal pain (all P < 0.05). Furthermore, the number of healthy individuals with myalgia was marginally higher compared to the CKD patients (P = 0.057). Data regarding the number of CKD patients with/without COVID‑19 infection throughout different CKD stages revealed that there was no significant difference between the two groups in terms of COVID‑19 infection in different stages of CKD (P = 0.956).

We found that some of the clinical presentations of COVID‑19 including common cold symptoms, cough, fever, sore throat, headache, anosmia, dyspnea, and abdominal pain were higher among healthy individuals compared to the CKD group. On the other hand, the susceptibility to COVID‑19 infection was not significantly different in various early stages of CKD.